생물 방위 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of biodefense Market

The global biodefense market was valued at USD 16.23 billion in 2025 and is projected to grow to USD 17.75 billion in 2026, reaching USD 26.88 billion by 2034, registering a CAGR of 5.32% during the forecast period. In 2025, North America dominated the global market with a 42.97% share, driven by strong government investment, advanced healthcare infrastructure, and active participation from biotechnology and pharmaceutical companies.

Biodefense refers to a comprehensive system of strategies, technologies, and policies designed to protect populations, ecosystems, and national security from biological threats. These threats may arise from natural outbreaks, accidental releases, or deliberate biological attacks. Biodefense initiatives typically include vaccine development, pathogen detection systems, biosurveillance, and emergency response preparedness. The growing risks of pandemics, bioterrorism, and emerging infectious diseases are major factors accelerating investments in this sector.

Impact of the Russia-Ukraine Conflict

The ongoing Russia-Ukraine conflict has heightened global awareness of unconventional warfare risks, including the potential use of biological agents. This geopolitical situation has encouraged governments and defense organizations to strengthen biodefense capabilities and invest more heavily in biosurveillance, rapid diagnostics, and medical countermeasures.

The war has also exposed vulnerabilities in healthcare systems and supply chains, pushing nations to enhance domestic production of vaccines and protective equipment. Many countries have increased research funding for pathogen detection technologies and biosecurity infrastructure. Consequently, the conflict has indirectly accelerated biodefense spending, particularly in North America and Europe, as governments focus on strengthening pandemic preparedness and national security.

Market Dynamics

Market Drivers

Increasing Awareness of Biological Risks

Growing awareness of biological threats, combined with government initiatives, is driving biodefense market growth. Governments worldwide are investing heavily in vaccine stockpiling, pathogen detection systems, and advanced biosurveillance technologies. For example, in April 2025, Parsons Corporation received a USD 24 million contract from the Naval Medical Research Command to improve infectious disease detection research.

Technological innovations such as artificial intelligence (AI), machine learning, IoT-enabled biosensors, and rapid diagnostics are improving the speed and accuracy of biological threat detection. In addition, research breakthroughs-such as the nanopore-based biosensor developed at the University of Missouri in 2023-are advancing biosensor capabilities for early disease detection.

Market Restraints

High Development Costs and Regulatory Challenges

Despite strong demand, the biodefense market faces several challenges. Developing vaccines, diagnostics, and therapeutics for biological threats requires extensive research, clinical trials, and regulatory approvals, resulting in very high R&D costs.

Many biodefense products target rare diseases, making it difficult to conduct large clinical trials or demonstrate product effectiveness. Additionally, strict regulatory requirements and liability risks discourage some companies from investing in this sector. Without guaranteed government procurement contracts, companies may struggle to recover development costs.

Market Opportunities

Rising Biological Threats and Technological Advancements

The increasing occurrence of infectious diseases and pandemic threats presents significant growth opportunities. The COVID-19 pandemic demonstrated the importance of rapid detection systems and scalable vaccine production platforms.

Emerging technologies such as AI-powered biosurveillance, IoT-based biosensors, and genomic sequencing tools are creating new opportunities for early detection and response to biological threats. Furthermore, collaboration between governments, research institutions, and private companies is accelerating innovation and improving global preparedness against biological hazards.

Biodefense Market Trends

Integration of Advanced Technologies

Technological innovation is transforming biodefense capabilities. Artificial intelligence and machine learning are increasingly used for pathogen identification, outbreak prediction, and risk assessment.

For instance, TeselaGen Biotechnology partnered with BioMADE in 2022 to develop AI-driven data platforms that support fermentation-based biomanufacturing and biological threat response.

Additionally, advancements in biotechnology and genetic engineering are enabling the development of new vaccine platforms, rapid diagnostic tests, and advanced sterilization technologies. These innovations are expected to strengthen global biodefense infrastructure and improve preparedness against future biological emergencies.

Segmentation Analysis

By Technology

Based on technology, the market includes UV light, gamma radiation, cold plasma, microwave heating, and others.

The UV light segment accounted for the largest share in 2025 and is expected to be the fastest-growing segment. UV technology is widely used for sterilization and decontamination because it effectively inactivates microorganisms such as bacteria, viruses, and fungi. Increasing biosecurity awareness and demand for disinfection technologies after the COVID-19 pandemic are driving its growth.

By System

The market is categorized into digital biosurveillance networks, early warning systems, biohazard detection systems, AI-assisted surveillance systems, biosensors, and others.

The biohazard detection systems segment is projected to account for 35.19% of the market share in 2026, as these systems play a crucial role in identifying biological threats quickly. Meanwhile, the biosensors segment is expected to grow the fastest due to increasing demand for portable and highly sensitive pathogen detection devices.

By End User

The market is segmented into military forces, homeland security, hospitals & clinics, pharmaceutical & biotech companies, and virological research institutes.

The military forces segment is expected to dominate the market with a 36.61% share in 2026, as armed forces require advanced protective equipment, vaccines, and detection systems to safeguard personnel from biological threats.

The pharmaceutical & biotech companies segment is projected to be the fastest-growing due to rising investments in vaccine development, therapeutics, and diagnostic technologies.

Regional Outlook

North America

North America dominated the biodefense market in 2025, reaching USD 6.97 billion. The United States leads the regional market due to strong government initiatives and programs such as Project BioShield and BARDA. The U.S. market is projected to reach USD 7.41 billion by 2026.

Europe

Europe is expected to be the fastest-growing regional market due to increasing government funding for biosecurity and research programs. Countries such as the U.K. and Germany are investing heavily in biodefense technologies, with projected market sizes of USD 0.71 billion and USD 0.62 billion respectively by 2026.

Asia Pacific

Asia Pacific is witnessing strong growth due to rising public health concerns and increased investments in disease surveillance systems. By 2026, the market size is projected to reach USD 3.48 billion in China, USD 0.65 billion in India, and USD 0.44 billion in Japan.

Middle East & Africa and Latin America

These regions are expected to experience moderate growth due to increasing awareness of biological threats, government initiatives, and expanding biotechnology research activities.

Competitive Landscape

The biodefense market is highly competitive, with major players focusing on innovation, partnerships, and acquisitions to strengthen their positions. Key companies include AirBoss Defense Group, Emergent BioSolutions, SIGA Technologies, Bio Rad Laboratories, and Smiths Detection.

Recent developments include vaccine approvals, government procurement contracts, and collaborations aimed at strengthening global biological threat response capabilities.

Conclusion

The biodefense market is expected to grow steadily from USD 16.23 billion in 2025 to USD 26.88 billion by 2034, driven by rising concerns about pandemics, biological warfare, and emerging infectious diseases. Increasing government investments, technological innovations such as AI-based biosurveillance and advanced biosensors, and growing public-private collaborations are shaping the future of the industry.

While challenges such as high R&D costs and regulatory complexities remain, expanding global preparedness for biological threats will continue to drive demand for vaccines, detection systems, and biosurveillance technologies. North America will likely maintain its leadership, while Europe and Asia Pacific emerge as key growth regions in the coming decade.

By Segmentation By Technology

• UV Light
• Gamma Radiation
• Cold Plasma
• Microwave Heating
• Others

By System

• Digital Biosurveillance Networks
• Early Warning Systems
• Biohazard Detection Systems
• AI-Assisted Surveillance System
• Biosensors
• Others

By End User

• Military Forces
• Homeland Security
• Hospitals & Clinics
• Pharmaceutical & Biotech Companies
• Virological Research Institutes

By Region

• North America (By Technology, By System, By End User, By Country)
  • U.S. (By End User)
  • Canada (By End User)
• Europe (By Technology, By System, By End User, By Country)
  • U.K. (By End User)
  • Germany (By End User)
  • France (By End User)
  • Russia (By End User)
  • Rest of Europe (By End User)
• Asia Pacific (By Technology, By System, By End User, By Country)
  • China (By End User)
  • India (By End User)
  • Japan (By End User)
  • South Korea (By End User)
  • Rest of Asia Pacific (By End User)
• Middle East & Africa (By Technology, By System, By End User, By Country)
• Iran (By End User)
  • Israel (By End User)
  • Saudi Arabia (By End User)
  • Turkey (By End User)
  • Rest of Middle East & Africa (By End User)
• Latin America (By Technology, By System, By End User, By Country)
  • Brazil (By End User)
  • Argentina (By End User)
  • Mexico (By End User)
  • Rest of Latin America (By End User)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Key Industry Developments - Key Contracts & Agreements, Mergers, Acquisitions and Partnerships
• 4.2. Latest Technological Advancements
• 4.3. Porters Five Forces Analysis
• 4.4. Supply Chain Analysis
• 4.5. Qualitative Insights - Impact of COVID-19 Pandemic on Global Biodefense Market
• 4.6. Regulatory Analysis on Global Biodefense Market

5. Global Biodefense Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Definition
• 5.2. Market Analysis, Insights and Forecast - By Technology
  • 5.2.1. Microwave Heating
  • 5.2.2. UV Light
  • 5.2.3. Gamma Radiation
  • 5.2.4. Cold Plasma
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By System
  • 5.3.1. Digital Biosurveillance Networks
  • 5.3.2. Early Warning Systems
  • 5.3.3. Biohazard Detection Systems
  • 5.3.4. AI-Assisted Surveillance System
  • 5.3.5. Biosensors
  • 5.3.6. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Military Forces
  • 5.4.2. Homeland Security
  • 5.4.3. Hospitals & Clinics
  • 5.4.4. Pharmaceutical & Biotech Companies
  • 5.4.5. Virological Research Institutes
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Middle East & Africa
  • 5.5.5. Latin America

6. North America Biodefense Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Technology
  • 6.1.1. Microwave Heating
  • 6.1.2. UV Light
  • 6.1.3. Gamma Radiation
  • 6.1.4. Cold Plasma
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By System
  • 6.2.1. Digital Biosurveillance Networks
  • 6.2.2. Early Warning Systems
  • 6.2.3. Biohazard Detection Systems
  • 6.2.4. AI-Assisted Surveillance System
  • 6.2.5. Biosensors
  • 6.2.6. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Military Forces
  • 6.3.2. Homeland Security
  • 6.3.3. Hospitals & Clinics
  • 6.3.4. Pharmaceutical & Biotech Companies
  • 6.3.5. Virological Research Institutes
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. Market Analysis, Insights and Forecast - By End User
      • 6.4.1.1.1. Military Forces
      • 6.4.1.1.2. Homeland Security
      • 6.4.1.1.3. Hospitals & Clinics
      • 6.4.1.1.4. Pharmaceutical & Biotech Companies
      • 6.4.1.1.5. Virological Research Institutes
  • 6.4.2. Canada
    • 6.4.2.1. Market Analysis, Insights and Forecast - By End User
      • 6.4.2.1.1. Military Forces
      • 6.4.2.1.2. Homeland Security
      • 6.4.2.1.3. Hospitals & Clinics
      • 6.4.2.1.4. Pharmaceutical & Biotech Companies
      • 6.4.2.1.5. Virological Research Institutes

7. Europe Biodefense Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Technology
  • 7.1.1. Microwave Heating
  • 7.1.2. UV Light
  • 7.1.3. Gamma Radiation
  • 7.1.4. Cold Plasma
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By System
  • 7.2.1. Digital Biosurveillance Networks
  • 7.2.2. Early Warning Systems
  • 7.2.3. Biohazard Detection Systems
  • 7.2.4. AI-Assisted Surveillance System
  • 7.2.5. Biosensors
  • 7.2.6. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Military Forces
  • 7.3.2. Homeland Security
  • 7.3.3. Hospitals & Clinics
  • 7.3.4. Pharmaceutical & Biotech Companies
  • 7.3.5. Virological Research Institutes
• 7.4. Market Analysis, Insights and Forecast - By Country
  • 7.4.1. U.K.
    • 7.4.1.1. Market Analysis, Insights and Forecast - By End User
      • 7.4.1.1.1. Military Forces
      • 7.4.1.1.2. Homeland Security
      • 7.4.1.1.3. Hospitals & Clinics
      • 7.4.1.1.4. Pharmaceutical & Biotech Companies
      • 7.4.1.1.5. Virological Research Institutes
  • 7.4.2. Germany
    • 7.4.2.1. Market Analysis, Insights and Forecast - By End User
      • 7.4.2.1.1. Military Forces
      • 7.4.2.1.2. Homeland Security
      • 7.4.2.1.3. Hospitals & Clinics
      • 7.4.2.1.4. Pharmaceutical & Biotech Companies
      • 7.4.2.1.5. Virological Research Institutes
  • 7.4.3. France
    • 7.4.3.1. Market Analysis, Insights and Forecast - By End User
      • 7.4.3.1.1. Military Forces
      • 7.4.3.1.2. Homeland Security
      • 7.4.3.1.3. Hospitals & Clinics
      • 7.4.3.1.4. Pharmaceutical & Biotech Companies
      • 7.4.3.1.5. Virological Research Institutes
  • 7.4.4. Russia
    • 7.4.4.1. Market Analysis, Insights and Forecast - By End User
      • 7.4.4.1.1. Military Forces
      • 7.4.4.1.2. Homeland Security
      • 7.4.4.1.3. Hospitals & Clinics
      • 7.4.4.1.4. Pharmaceutical & Biotech Companies
      • 7.4.4.1.5. Virological Research Institutes
  • 7.4.5. Rest of Europe
    • 7.4.5.1. Market Analysis, Insights and Forecast - By End User
      • 7.4.5.1.1. Military Forces
      • 7.4.5.1.2. Homeland Security
      • 7.4.5.1.3. Hospitals & Clinics
      • 7.4.5.1.4. Pharmaceutical & Biotech Companies
      • 7.4.5.1.5. Virological Research Institutes

8. Asia Pacific Biodefense Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Technology
  • 8.1.1. Microwave Heating
  • 8.1.2. UV Light
  • 8.1.3. Gamma Radiation
  • 8.1.4. Cold Plasma
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By System
  • 8.2.1. Digital Biosurveillance Networks
  • 8.2.2. Early Warning Systems
  • 8.2.3. Biohazard Detection Systems
  • 8.2.4. AI-Assisted Surveillance System
  • 8.2.5. Biosensors
  • 8.2.6. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Military Forces
  • 8.3.2. Homeland Security
  • 8.3.3. Hospitals & Clinics
  • 8.3.4. Pharmaceutical & Biotech Companies
  • 8.3.5. Virological Research Institutes
• 8.4. Market Analysis, Insights and Forecast - By Country
  • 8.4.1. China
    • 8.4.1.1. Market Analysis, Insights and Forecast - By End User
      • 8.4.1.1.1. Military Forces
      • 8.4.1.1.2. Homeland Security
      • 8.4.1.1.3. Hospitals & Clinics
      • 8.4.1.1.4. Pharmaceutical & Biotech Companies
      • 8.4.1.1.5. Virological Research Institutes
  • 8.4.2. India
    • 8.4.2.1. Market Analysis, Insights and Forecast - By End User
      • 8.4.2.1.1. Military Forces
      • 8.4.2.1.2. Homeland Security
      • 8.4.2.1.3. Hospitals & Clinics
      • 8.4.2.1.4. Pharmaceutical & Biotech Companies
      • 8.4.2.1.5. Virological Research Institutes
  • 8.4.3. Japan
    • 8.4.3.1. Market Analysis, Insights and Forecast - By End User
      • 8.4.3.1.1. Military Forces
      • 8.4.3.1.2. Homeland Security
      • 8.4.3.1.3. Hospitals & Clinics
      • 8.4.3.1.4. Pharmaceutical & Biotech Companies
      • 8.4.3.1.5. Virological Research Institutes
  • 8.4.4. South Korea
    • 8.4.4.1. Market Analysis, Insights and Forecast - By End User
      • 8.4.4.1.1. Military Forces
      • 8.4.4.1.2. Homeland Security
      • 8.4.4.1.3. Hospitals & Clinics
      • 8.4.4.1.4. Pharmaceutical & Biotech Companies
      • 8.4.4.1.5. Virological Research Institutes
  • 8.4.5. Rest of Asia Pacific
    • 8.4.5.1. Market Analysis, Insights and Forecast - By End User
      • 8.4.5.1.1. Military Forces
      • 8.4.5.1.2. Homeland Security
      • 8.4.5.1.3. Hospitals & Clinics
      • 8.4.5.1.4. Pharmaceutical & Biotech Companies
      • 8.4.5.1.5. Virological Research Institutes

9. Middle East & Africa Biodefense Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Technology
  • 9.1.1. Microwave Heating
  • 9.1.2. UV Light
  • 9.1.3. Gamma Radiation
  • 9.1.4. Cold Plasma
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By System
  • 9.2.1. Digital Biosurveillance Networks
  • 9.2.2. Early Warning Systems
  • 9.2.3. Biohazard Detection Systems
  • 9.2.4. AI-Assisted Surveillance System
  • 9.2.5. Biosensors
  • 9.2.6. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Military Forces
  • 9.3.2. Homeland Security
  • 9.3.3. Hospitals & Clinics
  • 9.3.4. Pharmaceutical & Biotech Companies
  • 9.3.5. Virological Research Institutes
• 9.4. Market Analysis, Insights and Forecast - By Country
  • 9.4.1. Iran
    • 9.4.1.1. Market Analysis, Insights and Forecast - By End User
      • 9.4.1.1.1. Military Forces
      • 9.4.1.1.2. Homeland Security
      • 9.4.1.1.3. Hospitals & Clinics
      • 9.4.1.1.4. Pharmaceutical & Biotech Companies
      • 9.4.1.1.5. Virological Research Institutes
  • 9.4.2. Israel
    • 9.4.2.1. Market Analysis, Insights and Forecast - By End User
      • 9.4.2.1.1. Military Forces
      • 9.4.2.1.2. Homeland Security
      • 9.4.2.1.3. Hospitals & Clinics
      • 9.4.2.1.4. Pharmaceutical & Biotech Companies
      • 9.4.2.1.5. Virological Research Institutes
  • 9.4.3. Saudi Arabia
    • 9.4.3.1. Market Analysis, Insights and Forecast - By End User
      • 9.4.3.1.1. Military Forces
      • 9.4.3.1.2. Homeland Security
      • 9.4.3.1.3. Hospitals & Clinics
      • 9.4.3.1.4. Pharmaceutical & Biotech Companies
      • 9.4.3.1.5. Virological Research Institutes
  • 9.4.4. Turkey
    • 9.4.4.1. Market Analysis, Insights and Forecast - By End User
      • 9.4.4.1.1. Military Forces
      • 9.4.4.1.2. Homeland Security
      • 9.4.4.1.3. Hospitals & Clinics
      • 9.4.4.1.4. Pharmaceutical & Biotech Companies
      • 9.4.4.1.5. Virological Research Institutes
  • 9.4.5. Rest of Middle East & Africa
    • 9.4.5.1. Market Analysis, Insights and Forecast - By End User
      • 9.4.5.1.1. Military Forces
      • 9.4.5.1.2. Homeland Security
      • 9.4.5.1.3. Hospitals & Clinics
      • 9.4.5.1.4. Pharmaceutical & Biotech Companies
      • 9.4.5.1.5. Virological Research Institutes

10. Latin America Biodefense Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Technology
  • 10.1.1. Microwave Heating
  • 10.1.2. UV Light
  • 10.1.3. Gamma Radiation
  • 10.1.4. Cold Plasma
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By System
  • 10.2.1. Digital Biosurveillance Networks
  • 10.2.2. Early Warning Systems
  • 10.2.3. Biohazard Detection Systems
  • 10.2.4. AI-Assisted Surveillance System
  • 10.2.5. Biosensors
  • 10.2.6. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Military Forces
  • 10.3.2. Homeland Security
  • 10.3.3. Hospitals & Clinics
  • 10.3.4. Pharmaceutical & Biotech Companies
  • 10.3.5. Virological Research Institutes
• 10.4. Market Analysis, Insights and Forecast - By Country
  • 10.4.1. Brazil
    • 10.4.1.1. Market Analysis, Insights and Forecast - By End User
      • 10.4.1.1.1. Military Forces
      • 10.4.1.1.2. Homeland Security
      • 10.4.1.1.3. Hospitals & Clinics
      • 10.4.1.1.4. Pharmaceutical & Biotech Companies
      • 10.4.1.1.5. Virological Research Institutes
  • 10.4.2. Argentina
    • 10.4.2.1. Market Analysis, Insights and Forecast - By End User
      • 10.4.2.1.1. Military Forces
      • 10.4.2.1.2. Homeland Security
      • 10.4.2.1.3. Hospitals & Clinics
      • 10.4.2.1.4. Pharmaceutical & Biotech Companies
      • 10.4.2.1.5. Virological Research Institutes
  • 10.4.3. Mexico
    • 10.4.3.1. Market Analysis, Insights and Forecast - By End User
      • 10.4.3.1.1. Military Forces
      • 10.4.3.1.2. Homeland Security
      • 10.4.3.1.3. Hospitals & Clinics
      • 10.4.3.1.4. Pharmaceutical & Biotech Companies
      • 10.4.3.1.5. Virological Research Institutes
  • 10.4.4. Rest of Latin America
    • 10.4.4.1. Market Analysis, Insights and Forecast - By End User
      • 10.4.4.1.1. Military Forces
      • 10.4.4.1.2. Homeland Security
      • 10.4.4.1.3. Hospitals & Clinics
      • 10.4.4.1.4. Pharmaceutical & Biotech Companies
      • 10.4.4.1.5. Virological Research Institutes

11. Competitive Analysis

• 11.1. Global Market Rank Analysis (2025)
• 11.2. Competitive Dashboard

12. Company Profiles

• 12.1. AirBoss Defense Group, Inc. (U.S.)
  • 12.1.1. Overview
  • 12.1.2. Products & services
  • 12.1.3. SWOT Analysis
  • 12.1.4. Recent Developments
  • 12.1.5. Strategies
  • 12.1.6. Financials (Based on Availability)
• 12.2. Bioquell, An Ecolab Solution (U.S.)
  • 12.2.1. Overview
  • 12.2.2. Products & services
  • 12.2.3. SWOT Analysis
  • 12.2.4. Recent Developments
  • 12.2.5. Strategies
  • 12.2.6. Financials (Based on Availability)
• 12.3. Bio-Rad Laboratories, Inc. (U.S.)
  • 12.3.1. Overview
  • 12.3.2. Products & services
  • 12.3.3. SWOT Analysis
  • 12.3.4. Recent Developments
  • 12.3.5. Strategies
  • 12.3.6. Financials (Based on Availability)
• 12.4. BlueDot Inc. (Canada)
  • 12.4.1. Overview
  • 12.4.2. Products & services
  • 12.4.3. SWOT Analysis
  • 12.4.4. Recent Developments
  • 12.4.5. Strategies
  • 12.4.6. Financials (Based on Availability)
• 12.5. E4life Srl (Australia)
  • 12.5.1. Overview
  • 12.5.2. Products & services
  • 12.5.3. SWOT Analysis
  • 12.5.4. Recent Developments
  • 12.5.5. Strategies
  • 12.5.6. Financials (Based on Availability)
• 12.6. Emergent BioSolutions Inc. (U.S.)
  • 12.6.1. Overview
  • 12.6.2. Products & services
  • 12.6.3. SWOT Analysis
  • 12.6.4. Recent Developments
  • 12.6.5. Strategies
  • 12.6.6. Financials (Based on Availability)
• 12.7. SIGA Technologies, Inc. (U.S.)
  • 12.7.1. Overview
  • 12.7.2. Products & services
  • 12.7.3. SWOT Analysis
  • 12.7.4. Recent Developments
  • 12.7.5. Strategies
  • 12.7.6. Financials (Based on Availability)
• 12.8. Dynavax Technologies (U.S.)
  • 12.8.1. Overview
  • 12.8.2. Products & services
  • 12.8.3. SWOT Analysis
  • 12.8.4. Recent Developments
  • 12.8.5. Strategies
  • 12.8.6. Financials (Based on Availability)
• 12.9. Alnylam Pharmaceuticals, Inc. (U.S.)
  • 12.9.1. Overview
  • 12.9.2. Products & services
  • 12.9.3. SWOT Analysis
  • 12.9.4. Recent Developments
  • 12.9.5. Strategies
  • 12.9.6. Financials (Based on Availability)
• 12.10. Ichor Medical Systems Inc. (U.S.)
  • 12.10.1. Overview
  • 12.10.2. Products & services
  • 12.10.3. SWOT Analysis
  • 12.10.4. Recent Developments
  • 12.10.5. Strategies
  • 12.10.6. Financials (Based on Availability)
• 12.11. Bavarian Nordic A/S (Denmark)
  • 12.11.1. Overview
  • 12.11.2. Products & services
  • 12.11.3. SWOT Analysis
  • 12.11.4. Recent Developments
  • 12.11.5. Strategies
  • 12.11.6. Financials (Based on Availability)
• 12.12. SKAN AG (Switzerland)
  • 12.12.1. Overview
  • 12.12.2. Products & services
  • 12.12.3. SWOT Analysis
  • 12.12.4. Recent Developments
  • 12.12.5. Strategies
  • 12.12.6. Financials (Based on Availability)
• 12.13. Smiths Detection Group Ltd (U.K.)
  • 12.13.1. Overview
  • 12.13.2. Products & services
  • 12.13.3. SWOT Analysis
  • 12.13.4. Recent Developments
  • 12.13.5. Strategies
  • 12.13.6. Financials (Based on Availability)
• 12.14. Parsons Corporation (U.S.)
  • 12.14.1. Overview
  • 12.14.2. Products & services
  • 12.14.3. SWOT Analysis
  • 12.14.4. Recent Developments
  • 12.14.5. Strategies
  • 12.14.6. Financials (Based on Availability)